Le Lézard
Classified in: Health
Subject: FDA

Pollogen's Leading Home-Use Device, TriPollar Stop, Receives FDA Clearance


TEL AVIV, Israel, Aug. 14, 2019 /PRNewswire/ -- FDA has cleared Pollogen's RF home-use device ? TriPollar Stop ? for sale in the US. TriPollar Stop, the innovative home-use device developed by Pollogen, is based on the company's clinically-proven, patented RF technology, and has enjoyed broad market acceptance outside the US over the last few years.

Pollogen's leading Home-Use Device, TriPollar Stop, Receives FDA Clearance (PRNewsfoto/Pollogen Ltd)

"TriPollar Stop has been our flagship product for the home market," says Sharon Ravid, CEO of Pollogen, "and we are very excited about the opportunity to offer this device to home users in the US."

The TriPollar Stop device is indicated for the treatment of the face and the neck, eliminating aging signs, reducing lines and wrinkles and improving skin strength, texture and elasticity. By implementing Pollogen's innovation of triple-axis RF waves, the device introduces heat to the dermis, which induces regeneration of the basic building blocks of the skin ? collagen and elastin fibers. Results are visible immediately after the treatment and can be maintained via a cycle of repeated treatments.

TriPollar Stop is part of the TriPollar product line developed by Pollogen for home users. This exclusive product line is based on Pollogen's innovative technologies, all tried and tested by clinicians in the professional aesthetic device market. The ingenuity of the TriPollar line lies in the company's ability to take these technologies and present them to the users in a handy, comfortable device without compromising on the safety and the quality of results.

The TriPollar home-use devices, are created with the company's innovative development concept of Intelligent Biology ? achieving the desired aesthetic results by encouraging the natural processes of the body for renewal and rejuvenation. "We believe that home users today are not only concerned with the beauty per se but also seek health and ethics," explains Ravid. "All the TriPollar products work in sync under the umbrella of Intelligent Biology to achieve skin health and improvement in the most natural way our body can offer."

About Pollogen

Pollogen Ltd., a company of Lumenis, is a global leader in the medical and home-based aesthetics markets, providing innovative, safe, and effective solutions that enhance and expand the practice of medical aesthetics professionals, as well as private aesthetic customers. The company offers products to support a range of skin treatments, based on its proprietary technologies, namely Tripollar RF, Voluderm, Trifractional, Oxygeneo and DMA. Pollogen provides solutions for professionals and consumers in more than 60 countries, addressing the specific needs of its professional clients and private customers in the dynamic aesthetic industry. For more information visit: www.pollogen.com

About Lumenis 

Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic, Surgical, and Ophthalmology markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. Lumenis is a portfolio company of XIO Group, a global alternative investments firm headquartered in London. For more information visit: www.lumenis.com

Contact information:
Michele Michaeli
[email protected]

 

SOURCE Pollogen Ltd


These press releases may also interest you

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:05
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...

at 00:00
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...

24 avr 2024
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.   During an illustrious 30-year...

24 avr 2024
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug...

24 avr 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...



News published on and distributed by: